You are here

FDA Approves Pegfilgrastim Biosimilar for Cancer

New Drug Reduces Infection in Chemotherapy Patients

The FDA has approved Udenyca (pegfilgrastim-cbqv, Coherus BioSciences, Redwood City, California) for patients with cancer who are receiving myelosuppressive chemotherapy. Pegfilgrastim-cbqv is a leukocyte growth factor designed to reduce infections as indicated by febrile neutropenia.

The drug is contraindicated for patients who have a history of serious allergic reaction to human granulocyte colony-stimulating factors and is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

The most common adverse reactions associated with pegfilgrastim-cbqv are bone pain and pain in extremities.

Pegfilgrastim-cbqv is Coherus’ first drug to receive approval from the FDA and has also been approved for use in Europe after receiving a favorable response from the European Medicines Agency’s Committee for Human Use in July of this year.

Source: GlobeNewswire, November 5, 2018; Healio.com, November 5, 2018

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
National Statistics Report Factors In Race, Ethnicity for the First Time